March 17, 2015
Sanofi K.K. announced on March 16 that alirocumab, a fully human antibody that targets proprotein convertase subtilisin/kexin type 9 (PCSK9), has met its primary efficacy endpoint in ODYSSEY JAPAN, a domestic PIII clinical trial conducted in Japanese hypercholesterolemia patients. The...read more